Ark Biopharmaceutical Secures China Approval for ADHD Drug Azstarys, Eyeing U.S. Financial Upside
“Ark Biopharmaceutical has received marketing authorization from China’s NMPA for Azstarys, a novel ADHD treatment combining serdexmethylphenidate and dexmethylphenidate for patients aged 6 and older. This milestone taps into China’s massive ADHD market affecting over 23 million children and adolescents, promising revenue streams via licensing deals with U.S. partner Zevra Therapeutics amid rising global demand … Read more